ANP Bioactivity in Obese Hypertensives To the Editor: I write to comment on and to question features of the recent publication from Dessi-Fulgheri and colleagues that appeared in the February issue of Hypertension (Hypertension. 1999:33;658–662). The authors report that a bolus injection of ANP produces greater falls in blood pressure, greater increases in plasma cyclic GMP, and a greater suppr...

The aim of this work was to ascertain, in nonmodulating essential hypertension, whether the abnormality in the renal blood supply is extended to the extremities and showed a similar response to ACE inhibition and whether these abnormalities could be identified in normotensive offspring of hypertensives, as non-modulation is a familial process with genetic underpinnings. We measured forearm vasc...

Hypertensive patients with clinical blood pressure (BP) uncontrolled on ≥3 antihypertensive medications (ie, apparent treatment-resistant hypertension [aTRH]) comprise ≈28% to 30% of all uncontrolled patients in the United States. However, the proportion receiving these medications in optimal doses is unknown; aTRH is used because treatment adherence and measurement artifacts were not available...

The aim of the study was to assess the relationship between systolic blood pressure during maximal treadmill test (SBP9mtt)) and flow-mediated vasodilation (FMD). Abnormal rise of SBP(mtt) is the phenomenon more frequent in hypertensive persons but it could be found in normotensive subjects too. 199 subjects referred to treadmill test were enrolled in the study. Four groups were formed: hyperte...

SUmAMRY Systolic and diastolic time intervals were studied non-invasively in a group of untreated hypertensives (n = 19) and a reference group (n = 36), all derived from a random population sample of 50-year-old men, and in a myocardial infarct group (n = 67) representative ofmen aged 48 to 57 years surviving infarction. The results showed that only the electromechanical interval, pressure rise...

The HYVET clinical trial (Hypertension in the Very Elderly Trial). HYVET is designed to observe the benefits and risks of reducing blood pressure in very elderly hypertensives (aged 80 or more) and is the largest clinical trial in very elderly hypertensives. 3845 patients participated in the HYVET study from 11 different countries. The trial showed reductions of 21% in total deaths, 39% in stro...